Swedish registers to examine drug safety and clinical issues in RA
- 1 June 2006
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 65 (6), 707-712
- https://doi.org/10.1136/ard.2005.045872
Abstract
Data from several different monitoring systems are examined. The potential for registers based on data obtained from clinical practice, and linkage of such data to national health and population registers, is discussed. The approach described is a possible prototype for long term surveillance systems needed for the safe introduction of new treatments.Keywords
This publication has 30 references indexed in Scilit:
- Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonistsAnnals Of The Rheumatic Diseases, 2005
- COX-2 Inhibitors — Lessons in Drug SafetyNew England Journal of Medicine, 2005
- Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?Annals Of The Rheumatic Diseases, 2004
- Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project)Annals Of The Rheumatic Diseases, 2004
- Postmarketing Surveillance and Adverse Drug ReactionsJAMA, 1999
- Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control studyBMJ, 1998
- Country profile: Sweden.1996
- The rationale for a post-marketing surveillance*Human Reproduction, 1987
- ARAMIS (the American Rheumatism Association Medical Information System). A prototypical national chronic-disease data bank.1986
- The person-number systems of Sweden, Norway, Denmark, and Israel.1980